← All trials
NCT01939301
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2013
- Primary completion
- Oct 1, 2017
- Completion date
- Feb 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 78
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Indiana UniversityLead sponsor
- Indiana UniversityOverall official - principal investigator
- MallinckrodtCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- Indiana UniversityReponsible party - principal investigator
- National Institutes of Health (NIH)Collaborator
- University of MississippiCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.